Best Peptides for Sleep & Longevity: Epithalon, MOTs-C, DSIP (2026)

There is no one anti-aging drug. Aging is a distributed process, and any intervention that meaningfully matters will usually target only one or two hallmark clusters at a time rather than everything at once.

• Epithalon targets telomere attrition, epigenetic drift, and circadian disruption through the pineal-melatonin axis.
• MOTS-c targets mitochondrial dysfunction, metabolic dysregulation, and some aspects of proteostasis.
• DSIP targets sleep architecture, which sits upstream of recovery, growth hormone release, glymphatic clearance, and a lot of what people informally lump into longevity.

None of these replaces the basics. Sleep hygiene, resistance training, Zone-2 cardio, protein intake, and daylight exposure still do most of the work. These peptides only start to make sense after those foundations are already in place.

Also spelled: Epitalon, Epithalone, AEDG peptide. Sequence: Ala-Glu-Asp-Gly. Developed by: Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology in the 1980s.

Mechanism: Epithalon works through two connected mechanisms. First, it appears to upregulate hTERT and activate telomerase, which is why it gets framed as a telomere peptide^[1][13]. Second, it appears to restore pineal-gland signaling and age-declined melatonin output. In aged rhesus monkeys, it restored a more youthful nighttime melatonin pattern and normalized cortisol rhythms^[14]. That is why subjective sleep improvement often shows up within the first few nights, long before any plausible telomere effect.

Clinical evidence: Epithalon has the longest human observational dataset of any peptide in this guide. Khavinson's work reported lower mortality over 6-, 12-, and 15-year follow-up windows in older adults and coronary patients treated with epithalamin or related protocols^[2][3]. The real caveat is that most of that dataset comes from one research group without comparable Western replication at similar scale^[6].

The most common published and clinic-used version is a 10-day run at 10 mg/day at bedtime^[16][17]. A 20-day cycle exists in the Khavinson orbit, but more is not clearly better. Running more than three cycles per year is not well supported by the evidence I could find.

Timing matters. Bedtime injection makes sense because Epithalon is the only peptide in this guide with an explicit pineal-circadian rationale.

For a 10-day cycle at 10 mg/day, the cost-efficient move is usually a 50 mg vial reconstituted with 2.5 mL of BAC water, giving 20 mg/mL and a 10 mg dose at 50 units. Use the PepPal Peptide Reconstitution Calculator for custom vial sizes or if your supplier sends something non-standard.

Side effects: Epithalon has one of the cleaner community and published safety profiles, with mild injection-site irritation, mild headache early in a cycle, and vivid dreams being the main recurring notes^[1][16]. Active or recent malignancy is the biggest theoretical contraindication because telomerase activation is not something to be casual about, even though some animal work suggested oncostatic rather than pro-tumor effects^[15][18].

Full name: Mitochondrial Open Reading Frame of the 12S rRNA Type-C. Sequence: a 16-amino-acid peptide encoded by mitochondrial DNA, not nuclear DNA.

Mechanism: MOTS-c is unusual because it is mitochondrial-derived and appears to move into the nucleus during metabolic stress to regulate gene expression. Its main frame of relevance is AMPK activation, which is why it is often described as an exercise-mimetic or exercise-adaptation amplifier^[4][5][19].

Clinical evidence: MOTS-c has not completed a formal human treatment trial in its base form. The closest human signal comes from CB4211, a MOTS-c analog that completed early-phase testing and showed a favorable safety profile with encouraging metabolic trends^[7]. What we actually have for MOTS-c itself is strong and consistent preclinical work across insulin sensitivity, diet-induced obesity, exercise capacity, and age-related decline^{[4][5][19][21]}.

Practitioner dosing is more variable here than with Epithalon. Most real-world protocols cluster around 5-10 mg two to three times weekly^[17][22]. Pre-workout timing is common, but the guide evidence does not hinge on exact clock timing the same way Epithalon does.

Most community protocols use 1.0 mL reconstitution on a 10 mg vial, which makes a 5 mg dose equal 50 units. That keeps the injection practical. If you need custom volumes, use the PepPal calculator.

Side effects: USADA's review and community reports flag palpitations, injection-site irritation, fever, and occasional insomnia, especially at higher doses^[20]. Because MOTS-c and metformin both point at AMPK, a theoretical additive effect is worth flagging even though there is no good human interaction dataset yet^[7].

For the full technical breakdown, see the MOTS-c protocol page on Peptide Dosing Protocols.

Full name: Delta Sleep-Inducing Peptide, also called Emideltide in some FDA 503A filings. Sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu.

Mechanism: DSIP was isolated from cerebral venous blood during experimentally induced slow-wave sleep in rabbits in 1974^[8]. Its exact mechanism remains incomplete, but the most consistent findings are slow-wave sleep promotion, cortisol modulation, and broader neuroregulatory effects^[9][10].

Clinical evidence: DSIP has some of the oldest sleep-related clinical data in the peptide space, but the studies are small and inconsistent. Chronic-insomnia and chronic-pain pilots showed real signal, and older withdrawal studies reported striking symptom-improvement numbers, but this is not a modern, large-scale evidence base^[9][24][25].

DSIP has a short biological half-life, which makes injection timing more sensitive than either Epithalon or MOTS-c. Most people start at the low end around 100 mcg because the main downside of overshooting is next-day grogginess^[9].

Lower-concentration reconstitutions are usually more practical for DSIP because the doses are so small. It is easier to reliably draw 10 units than 2 units, so newer users are usually better off diluting toward ease of measurement rather than tiny high-concentration pulls. Verify with the PepPal calculator.

Side effects: The most common problems are daytime grogginess, vivid dreams, mild headache, and injection-site reactions^[9]. No good long-term human safety dataset exists.

Start with Epithalon if your goal is broad longevity with the largest human dataset and a meaningful chance of faster sleep-quality improvement. A short 10-day bedtime cycle is the cleanest entry point.

Start with MOTS-c if the real target is metabolic healthspan, insulin sensitivity, or exercise adaptation. It is the best choice when the bottleneck is energy systems rather than sleep architecture.

Start with DSIP only if sleep architecture is the main problem and you have already fixed the obvious basics such as caffeine cutoff, schedule drift, and sleep hygiene. It is a more surgical tool than the other two.

Can you stack them? Yes. The common community framing is Epithalon in short annual or semi-annual cycles, MOTS-c ongoing two times weekly, and DSIP layered in only when sleep depth is a priority. For general stacking principles, see Peptide Stacking 101.

On April 15, 2026, the FDA published a 503A bulk drug substances update that directly affected all three compounds in this guide^[11][12].

• Epithalon was removed from Category 2 after nominations were withdrawn, with PCAC review set for July 24, 2026.
• MOTS-c was removed from Category 2 with PCAC review set for July 23, 2026.
• DSIP (Emideltide) was removed from Category 2 with PCAC review set for July 24, 2026.

Practically, that means all three exit the FDA's significant-safety-concerns bucket but none is yet sitting on a settled approved compounding list. That is a real regulatory improvement, but it is not the same as clean approval.

For the broader category context, see RFK Jr. on Peptides: FDA Category 2 Fact Check.

I only list suppliers I have already audited against Finnrick Analytics independent testing data.

• Peptide Partners carries Epithalon, MOTS-c, and DSIP. Across the catalog, it still has the deepest Finnrick testing depth I have audited, and PepPal readers can use code PEPPAL.
• Orbitrex Peptides carries all three as well and is a good fit when you want single-vial trial orders instead of building a larger cart.

For the full side-by-side supplier breakdown, use Peptide Partners vs Orbitrex. The guide referenced a non-existent /blog/top-peptide-suppliers-2026 route, so the closest current PepPal equivalent is Best Grey Market Peptide Suppliers (2026).

For BAC water, syringes, and prep gear, use Peptide Injection Supplies.

• Running Epithalon continuously. It is built around short intermittent cycles, not endless daily use.
• Treating MOTS-c as a fat-loss peptide. It is better framed as a metabolic-health and exercise-adaptation peptide. If fat loss is the main goal, use Best Peptides for Fat Loss.
• Overdosing DSIP. Above roughly 500 mcg, next-day grogginess often starts outweighing the sleep-quality upside.
• Skipping fundamentals. If caffeine timing, sleep schedule, and overall recovery hygiene are weak, peptides will not rescue the process.
• Ignoring active cancer history with Epithalon. Telomerase activation is not something to wave away casually.
• Ignoring Finnrick testing. These are still grey-market compounds and supplier verification matters.

• Reconstitution math: PepPal Peptide Reconstitution Calculator
• Supplier options with Finnrick data: Best Grey Market Peptide Suppliers (2026)
• Injection supplies: Peptide Injection Supplies
• External-aging companion guide: Best Peptides for Skin, Collagen & Anti-Aging
• Stacking principles: Peptide Stacking 101
• Full protocol page for MOTS-c: MOTS-c on Peptide Dosing Protocols
• Reconstitution walkthrough: How to Reconstitute Peptides
• Research methodology: About PepPal & Methodology